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1. Introduction 
The incidence of cranial nerve (CN) palsy is not uncommon in patients with untreated 
nasopharyngeal cancer (NPC). In the 7th edition of the American Joint Committee on Cancer 
(AJCC) Staging Manual, the AJCC recommended that CN involvement be assessed by 
neurological evaluation rather than by cross-sectional imaging (computed tomography [CT] 
and magnetic resonance imaging [MRI]), because CN involvement is considered a poor 
prognostic indicator in NPC patients, those with CN involvement are staged as T4. 
However, evaluation of CN palsy by clinical symptoms and physical examination has 
limitations. First, the accuracy of the neurological examination depends on the expertise of 
the examiner and the subjective report of the patient. Second, because CN involvement may 
be asymptomatic, it is difficult to diagnose CN palsy at an early stage by clinical 
neurological evaluation. In addition, neurological evaluation is not an optimal diagnostic 
method for assessing lesion localization and extension, which are critical factors in planning 
treatment, particularly in delineation of target volume. 
With the excellent soft tissue contrast resolution and multiplanar imaging capability of MRI, 
direct visualization of smaller nerves and nerve branches is possible, making MRI a valuable 
tool in detecting and defining the extent of CN involvement in NPC. The difference and 
relationship between MRI findings of CN involvement and the symptoms and signs of CN 
dysfunction have not been fully addressed. 
The goal of this study was to detect the difference and relationship between MRI findings 
suggestive of CN involvement and the symptoms and signs of CN dysfunction, and to 
evaluate the prognostic value of MRI-detected CN involvement in a large sample of 
consecutive patients. These information may contribute to understanding the patterns of 
spread and biological nature of NPC, and may also prove references in tumor staging and 
treatment planning. 
2. Patients and methods 
Patients: From January 2003 to December 2004, 924 consecutive patients with newly 
diagnosed untreated NPC were included in our study. There were 685 male patients and 
239 female patients, with a male-female ratio of 2.9:1, and the median age was 45 years 
(range, 11-78 years). All patients had a pretreatment evaluation that consisted of a 
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complete history, physical and neurologic examination, hematology and biochemistry 
profiles, MRI scan of the neck and nasopharynx, chest radiography, and abdominal 
sonography. Medical records and imaging studies were reviewed retrospectively, and all 
patients were staged according to criteria in the 6th edition of the AJCC Cancer Staging 
Manua. 
Imaging Protocol: MR scanning was performed with a 1.5-Tesla system (Signa CV/i, 
General Electric Healthcare) and a head and neck combined coil. The area from the 
suprasellar cistern to the inferior margin of the sternal end of the clavicle was examined. T1-
weighted fast spin-echo images in the axial, coronal, and sagittal planes (repetition time of 
500–600 milliseconds, echo time of 10–20 milliseconds, 5-mm slice thickness with 1-mm 
interslice gap for the axial plane, 6-mm slice thickness with 1-mm interslice gap for coronal 
and sagittal planes, and a 512*512 matrix) and T2-weighted fast spinecho MR images in the 
axial plane (repetition time of 4000–6000 milliseconds, echo time of 95–110 milliseconds, 5-
mm slice thickness with 1-mm interslice gap, and a 512*512 matrix) were obtained before 
injection of contrast agent. After intravenous gadolinium diethylenetriamine pentaacetic 
acid (Gd-DTPA; Magnevist, Schering, Berlin) injection at a dose of 0.1 mmol/kg of body 
weight, spin-echo T1-weighted axial and sagittal sequences, and spin-echo T1- weighted fat-
suppressed coronal sequences were performed sequentially, with parameters similar to 
those used before Gd-DTPA injection. 
2.1 Image assessment and diagnostic criteria 
Medical records and imaging studies were retrospectively analyzed. Cranial nerve palsy 
was diagnosed separately by two radiation oncologists who were unaware of the clinical 
findings, and clinical nerve palsy was diagnosed by others on the basis of clinical symptoms 
and a physical examination before treatment. Any disagreements were resolved by 
consensus. Two radiologists specializing in head and neck cancers, who were unaware of 
the clinical findings, evaluated the MRI images separately. Any disagreements were 
resolved by consensus. Soft tissue tumor was observed as intermediate signal intensity on 
pre-Gd-DTPA T1- and T2-weighted images and an enhancing mass on post-Gd-DTPA T1-
weighted images, replacing the normal anatomy of the structure. MRI-detected CN 
involvement had to meet one of the following criteria: 1) enhancement of soft tissue tumor 
along the course of the ipsilateral related nerve and replacing the normal structures of the 
CN on gadolinium-enhanced T1-weighted images [Fig.1]; or 2) perineural spread, defined as 
an enlargement or abnormal enhancement of the nerve, obliteration of the neural fat pads 
adjacent to the neurovascular foramina, and neuroforaminal enlargement [Fig.1] [1-3]. 
Because CNs in the parapharyngeal space could not be identified as isolated structures on 
MRI, parapharyngeal space invasion could not be regarded as evidence of CN involvement 
in our study.  
MRI-detected CN involvement at the following sites were assessed: extracranial segment of 
the maxillary nerve (V3), pterygopalatine fossa, foramen rotundum, foramen ovale, jugular 
foramen, hypoglossal canal, inferior orbital fissure, orbital apex, superior orbital fissure, 
cavernous sinus segment of CNs III-VI, trigeminal ganglion, and CNs in the cistern. By 
AJCC criteria, parapharyngeal and skull base invasion were classified as T2 and T3, 
respectively, and intracranial, infratemporal, hypopharynx, or orbital disease was classified 
www.intechopen.com
 
MRI-Detected Cranial Nerve Involvement in Nasopharyngeal Carcinoma 
 
125 
as T4 [4]. Thus, all MRI findings that were suggestive of CN involvement were classified 
into 2 categories: 1) extracranial or basicranial or 2) intracranial or orbital.  
 
Fig. 1. A palsied cranial nerve V3. The enhanced coronal T1-weighted coronal fat 
suppression image at the level of the foramen ovale shows the enhancing tumor extending 
intracranially via the enlarged right foramen ovale along V3 and into the trigeminal cistern. 
2.2 Treatment 
All patients were treated by definitive-intent radiation therapy. Our policy was to cover the 
nasopharynx and the retropharyngeal lymph nodes within the primary target in every 
radical attempt, and to treat patients with gross lymphadenopathy with whole-neck 
irradiation. Most patients (773 of 924 or 83.7%) were treated with conventional techniques, 
12.7% (118 of 924) with intensity-modulated radiation therapy (IMRT), and 3.6% (33 of 924) 
with 3-dimensional conformal radiation therapy (3-DCRT). Details regarding the radiation 
therapy techniques at the Cancer Center of Sun Yat-sen University have been reported 
previously [5-7]. 
Most patients (517 of 629 or 82.2%) with stage III or stage IV disease (classified as T3-T4 or 
N2-N3) received neoadjuvant (137 of 629 or 21.8%), concomitant (374 of 629 or 59.5%), or 
adjuvant chemotherapy (6 of 629 or 1.0%), in conjunction with a platinum-based therapeutic 
clinical trial. When possible, salvage treatments (including afterloading, surgery, and 
chemotherapy) were provided in the event of documented relapse or when the disease 
persisted despite therapy. 
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2.3 Statistical analysis 
Patients were followed up at least every 3 months during the first 2 years; thereafter, 
patients were followed up every 5 months until death. The median follow-up period for the 
whole group was 40 months (range, 2-56 months). All events were measured from the date 
of commencement of the treatment. The following endpoints (time to the first defining 
event) were assessed: overall survival (OS); local relapse-free survival (LRFS); and distant 
metastasis-free survival (DMFS). Local recurrence was established by fiberoptic endoscopy 
and biopsy and/or MRI. Distant metastases were diagnosed based on clinical symptoms, 
physical examination, and imaging methods including chest radiograph, bone scan, CT, and 
abdominal sonography.  
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS Inc., Chicago, IL) 12.0 software. The actuarial rates were calculated by the Kaplan-
Meier method [8], and the differences were compared by using the log-rank test. 
Multivariate analyses with the Cox proportional hazards model were used to test 
independent significance by backward elimination of insignificant explanatory variables [9]. 
Host factors (age and sex) were included as the covariates in all tests. The chi-square test 
was used to analyze the relationship between MRI findings and CN palsies. The criterion for 
statistical significance was set at a = 0.05. The P values were based on 2-sided tests. 
3. Results 
3.1 Clinical CN palsies and MRI-detected CN Involvement  
Of 924 patients with NPC, 82 (8.9%) patients initially presented with CN palsy. A total of 
134 CNs were found to be paralyzed, and 31 patients were detected with multiple CN 
palsies. In these 82 patients with CN palsy, 79 patients had one or more MRI findings 
demonstrating CN involvement, and CN V was the most common nerve to be involved. Of 
all patients, 46 (5.0%) had clinical evidence of trigeminal nerve palsy at presentation, 92 
(28%) divisions of palsied trigeminal nerves were clinically identified. Of these 46 patients, 
43 (93.5%) had unilateral paresthesia and 3 (6.5%) had bilateral paresthesia. In 5 of these 
patients with palsied nerves, MRI findings did not correspond to clinical findings. For 
example, a patient was detected with palsied CN V3, but MRI demonstrated only evidence 
of CN involvement of CN V2.  
A total of 333 (36%) patients demonstrated MRI-detected CN involvement and of the 514 
patients with local advanced (T3-4) disease, 332 patients demonstrated MRI-detected CN 
involvement. The incidence of MRI-detected CN involvement in T3 patients was lower than 
that in T4 patients (43.8% vs 97.5%, P = 0.000). Only 1 patient with T2 disease demonstrated 
MRI-detected CN involvement. Clinical signs and symptoms of ipsilaterally affected CNs 
were absent in 259 (77.8%) of patients with MRI-detected CN involvement. The correlation 
between MRI-detected CN involvement and ipsilateral CN palsy is shown in Table 1. 
3.2 Imaging basis of CN palsies 
Of the 134 paralyzed CNs, 98 (73.1%) demonstrated ipsilateral intracranial or orbital MRI-
detected CN involvement; 21 (15.7%) demonstrated basicranial MRI-detected CN 
involvement. No MRI evidence of CN involvement was observed in the remaining 15 
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(11.2%) paralyzed CNs; among these 15 CNs, carotid sheath (n=13) or retropharyngeal 
lymph node (n = 1) invasion could be identified along the course of the CNs paralyzed on 
the ipsilateral side; no tumor could be detected along the course of the remaining paralyzed 
CNs on the MRI images. Of the 92 divisions of palsied trigeminal nerves, 91 trigeminal 
nerve palsies (98.9%) showed MRI evidence of 1 or more trigeminal nerve involvements. 
However, no evidence could be found for the remaining 1 palsied V1 case on MR images. 
 
MRI-detecded CN involvement Sites number* Palsied CNs, Sites number 
Basicranial or extracranial
Extracranial part of V3 264 V3, 28 
Ovale foramen 223 V3, 28 
Pterygopalatine fossa 177 V2, 30 
Rotundum foramen 86 V2, 19 
Jugular foramen 48 IX, 1; X, 2；XI, 0 
Hypoglossal foramen 108 XII, 11 
Intracranial or orbital
Superior orbital fissure 6 III,1; IV,2; V1, 2; VI, 1 
Orbital apex 11 II, 5 
Inferior orbital fissure 36 V2, 14 
Cavernous segment of III 41 III,10 
Cavernous segment of IV 75 IV, 11 
Cavernous segment of V1 130 V1, 20 
Cavernous segment of V2 144 V2, 31 
Cavernous segment of VI 125 VI, 30 
Trigeminal ganglion 86 V, 24 
Cisternal part of V CN 9 V, 5 
Cisternal part of IX-XI  4 IX-XI, 0 
Cisternal part of XII  9 XII, 2 
*: Sites number means the number of MRI-detected CN involvement 
Table 1. The Correlation between MRI-detected CN Involvement and the Ipsilateral Related 
CN Palsy. 
3.3 Prognosis of MRI-detected CN Involvement in T3-4 disease 
In 514 T3-4 patients, significant differences were observed in 3-year OS (75.7% vs 89.2%,  
P = 0.001) and DMFS (77.1% vs 87.8%, P = 0.002) rates, with better rates observed in the 182 
patients who did not demonstrate MRI-detected CN involvement. No significant difference 
was observed in 3-year LRFS (86.8% vs 91.8%, P = 0.067) rates between the patients with and 
without MRI-detected CN involvement in T3-4 patients.  
Because most (97.5%) T4 patients had MRI-detected CN involvement, the prognoses 
between the T3 patients with and without MRI-detected CN involvement were also 
compared. All patients with local advanced disease (T3 and T4) in this series were classified 
into 3 groups: Group 1, T3 disease without MRI-detected CN involvement; Group 2, T3 
disease with MRI-detected CN involvement; and Group 3, T4 disease. Significant differences 
were observed in OS and DMFS rates between Groups 1 and 2 (P = 0.009 and P = 0.011, 
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respectively), but no significant differences were observed between Groups 2 and 3  
(P = 0.322 and P = 0.809, respectively). No significant differences were observed in the LRFS 
rates between Groups 1 and 2 (P = 0.750), and no significant difference was observed 
between Groups 2 and 3 (P = 0.079).  
Multivariate analysis was performed to adjust for various prognostic factors in T3 and T4 
disease. Parameters were included in the Cox proportional hazards model by backward 
elimination of insignificant explanatory variables: age (50<=years vs >50 years), sex, skull 
base extension, paranasal sinus extension, intracranial extension, infratemporal extension, 
orbital extension hypopharynx extension, MRI-detected CN involvement, CN palsy, N 
classification, radiotherapy technique, and chemotherapy. Both clinical CN palsy and MRI-
detected CN involvement were significant predictive factors for the DMFS and OS rates in 
local advanced disease (Table 2).  
 
Endpoint Variable B Exp(B) 




age -0.287 0.750 0.550-1.024 0.070 
MRI-detected CN involvement 0.866 2.377 1.620-3.489 0.000 
CN palsy -0.662 0.516 0.300-0.886 0.016 
intracranial extension 0.511 1.667 1.104-2.516 0.015 
N classification 0.487 1.627 1.396-1.898 0.000 
DMFS 
MRI-detected CN involvement 0.627 1.871 1.268-2.762 0.002 
CN palsy -0.506 0.603 0.330-1.102 0.100 
paranasal sinuses extension 0.509 1.665 1.087-2.547 0.019 
N classification 0.576 1.778 1.510-2.094 0.000 
LRFS 
age -0.379 0.685 0.457-1.026 0.066 
gender -0.855 0.425 0.232-0.779 0.006 
intracranial extension 0.787 2.197 1.424-3.389 0.000 
OS, overall survival; LRFS, local relapse-free survival; DMFS, metastasis-free survival. 
Table 2. Summary of Multivariate Analyses of Prognostic Factors in T3-4 Disease. 
3.4 Difference in the prognostic implications between clinical CN palsy and  
MRI-detected CN involvement  
In 336 patients with clinical and/or MRI-detected CN involvement, no significant difference 
was observed in the 3-year DMFS (74.6% vs 84.6%, P = 0.094) or LRFS (86.7% vs 87.9%, P =  
0.899) rates between patients with and without clinically detected CN palsies. A marginally 
significant difference was observed in the 3-year OS (74.2% vs 80.1%, P = 0.067) rate; 
however, after adjusting for N classification, there was no significant difference (P = 0.102).  
3.5 Prognosis of lesion localization in patients with MRI-detected CN involvement  
Of the 333 patients with MRI-detected CN involvement, no significant differences were 
observed with regard to the 3-year OS (78.3% vs 72.9%, P = 0.120), LRFS (89.7% vs 84.1%,  
P = 0.154) or DMFS (79.6% vs 74.8%, P = 0.466) rates between patients with and without 
intracranial or orbital MRI-detected CN involvement.  
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4.1 Difference between clinical CN palsy and MRI-detected CN involvement  
Clinical findings were not consistent with the MRI findings of CN involvement in some 
cases. Nerves are resistant to tumor, and perineural tumor spread is an insidious and often 
asymptomatic process. The incidence of MRI-detected CN involvement is high in NPC; 
patients are often asymptomatic [10]. According to our observation, the incidence of MRI-
detected CN involvement was much higher than that of clinical presentation of CN palsy in 
NPC patients.  
With improvement in imaging techniques, direct visualization of smaller nerves and 
proximal nerve branches have become possible. MRI allows contrast between the nerve 
fibers and the surrounding cerebrospinal fluid, perineural vascular plexus, and fat pads. 
Involvement of cranial nerves may be direct or perineural; proposed MRI criteria of cranial 
nerve involvement in our study include both possibilities. MRI, including the contrast-
enhanced fat suppression technique, is particularly helpful in detection of direct and 
perineural invasion of the nerve in patients with NPC, so we often identified cranial nerve 
involvement on gadoliniumenhanced T1-weighted images. Perineural spread, in which 
pathologic conditions spread along the connective tissues of the perineurium, is often 
associated with malignant disease of the head and neck. The imaging hallmark of this 
process has been discussed in detail in a previous articles [1-3]. 
Without contrast between the nerve and the surrounding structures, CNs in the 
parapharyngeal space could not be identified on MRI; therefore, parapharyngeal space 
invasion was not defined as evidence of CN involvement in our study. A small number of 
symptomatic patients with only carotid sheath or retropharyngeal lymph node invasion 
along the course of ipsilaterally paralyzed CNs were regarded as MRI negative but clinically 
positive in our series. 
Because NPC is a nonsurgical disease, the limitation of our study is that there was no 
pathologic correlation of CN involvement with MRI findings. Another limitation is the slice 
thickness of 5 mm used in our study, which may limit the sensitivity of detecting cranial 
nerve involvement. Ideally, slice thickness should be 3 to 4 mm in future studies; this may 
lead to earlier identification of CN involvement. 
4.2 Prognosis of clinical CN palsy in MRI-detected CN involvement 
We observed that most CN palsies had 1 or more MRI findings of intracranial or orbital CN 
involvement; this may be a reason for the adverse prognostic significance of CN palsies, and 
patients with CN palsies are determined to be at stage T4 [4]. 
Several investigators have reported that the perineural tumor spread in patients with non-
nasopharyngeal carcinoma of the head and neck is associated with an increased incidence of 
recurrence [11-14]. However, in our series, MRI-detected CN involvement was not 
associated with the 3-year LRFS rate in NPC patients with local advanced disease. The 
primary treatment modality for NPC was radiation therapy, whereas that of other 
carcinomas of the head and neck was surgery. Lawrence and Cottel reported that 
postoperative radiotherapy of squamous cell carcinoma with perineural invasion resulted in 
a much improved survival probability when compared with that observed after 
www.intechopen.com
 
Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma 
 
130 
conventional surgical excision [13]. Radiation therapy (relatively large treatment volume) 
provided better LRFS to patients with perineural spread. Early results of improved 
treatment strategies for nasopharyngeal carcinoma, including the boost technique of 2-
dimensional radiation therapy, use of IMRT, and combinationof chemotherapy with 
radiotherapy, has shown considerable improvement in LRFS [15-16]. Improved treatment 
might result in no significant difference with regard to the 3-year LRFS rate in patients with 
T3-4 disease with or without MRI findings of CN involvement. 
The LRFS in patients with intracranial or orbital CN involvement was so poor that there was 
little difference in the 3-year LRFS rate between T3 patients with MRI-detected CN 
involvement and T4 patients. This poor survival rate may be a result of difficulties 
encountered in designing a therapeutic strategy for these patients and limitations on the 
dose escalation for intracranial or orbital disease. Several studies have demonstrated that 
perineural tumor spread in other head and neck cancers may result in a higher incidence of 
distant metastases [17-18]. We found that MRI-detected CN involvement was associated 
with a greater propensity for distant metastasis and resulted in unfavorable outcome in OS. 
Batsakis reported that carcinoma proliferated along the nerves within the lymphatics of the 
epineurium and the perineural sheaths [19]. We presume that tumor proliferation within the 
lymphatics may increase the risk of distant metastasis. On the basis of our data, the pattern 
of treatment failure in the NPC patients with CN involvement is caused by distant 
metastases. This implies that tumors with perineural involvement are more aggressive and 
spread from the primary tumor site to distant organs. Understanding the perineural 
invasion at the molecular level is an important step toward identification of the prognostic 
markers and therapeutic targets for NPC treatment. 
Both clinical CN palsy and MRI-detected CN involvement were significant and independent 
predictive factors for the DMFS and OS rates in local advanced disease. In patients with 
clinical CN palsy or MRI-detected CN involvement, there is no real difference in the OS and 
DMFS between symptomatic and asymptomatic patients. This implies that MRI-detected 
involvement of CN itself has a poor prognosis in high-risk NPC irrespective of the clinical 
symptoms caused by such an involvement. In current AJCC Cancer Staging Manual, that CN 
involvement be assessed by neurological evaluation is recommended, rather than by cross-
sectional imaging. Therefore, MRI-detected CN involvement should be involved in the 
future staging system. 
4.3 Clinical value of MRI-detected CN involvement in treatment 
Almost all the patients with MRI-detected CN involvement were classified as T3-4. 
Concurrent chemoradiotherapy has emerged as the treatment of choice for locoregionally 
advanced (T3-4) NPC. Therefore, all patients with MRI-detected CN involvement should 
receive concurrent chemoradiotherapy. According to our data, these patients had a high 
distant metastasis rate; therefore, more intensive chemotherapy regimes should be 
considered.  
Chang et al demonstrated that MRI was associated with improved tumor control of patients 
with NPC and CN palsy [20]. Because MRI can be used to clearly detect the location and 
extent of CN invasion, MRI should be considered as a basic imaging modality in the 
delineation of the target volume, ensuring full coverage of the gross target target volume 
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and high-risk clinical target volume. A higher radiation dose improved tumor control and 
survival in NPC. We suggest that an adequate dose should be determined for these patients 
with MRI-detected CN involvement. 
4.4 Limitations of our study 
Prognosis may depend not only on the extent of disease on MRI but also on the effectiveness 
of treatment. Variability of treatment may be one of the limitations of our study. In our 
series, most patients with stage III and IV disease received chemotherapy, but some did not 
receive chemotherapy (patients with advanced age, heart disease, diabetes, and patients in 
the control group in a clinical trial). Although 3-DCRT/IMRT techniques were reported to 
provide excellent locoregional control for NPC, distant metastases are still the main cause of 
treatment failure [21]. In our series, only a small percentage of patients were treated with 
IMRT/3-DCRT because of resource limitations; however, when included as a covariate, 
radiation technique was not an independent prognostic factor for either distant failure or 
death in multivariate analyses. 
5. Summary 
The incidence of MRI-detected CN involvement in NPC is high and is often observed in 
asymptomatic patients, and the incidence of MRI-demonstrable trigeminal nerve 
involvement is much higher than other nevers. Disease with MRI-detected CN involvement 
has a poor prognosis, independent of lesion localization and symptoms in local advanced 
disease. 
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